HMOX1 and carcinoma: NACRT therapeutic efficacy and clinical outcomes in ESCC patients can be predicted by examining TXNRD1 and HO-1 expression status in carcinoma cells in pre-therapeutic endoscopic biopsy and surgically resected specimens.